Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ASX:NAB
ASX:NABBanks

Has National Australia Bank (ASX:NAB) Run Too Far After Strong Multi‑Year Share Gains

Wondering if National Australia Bank is reasonably priced at its current level, or if the recent run means you might be paying too much for the stock. The share price recently closed at A$43.37, with returns of 2.4% over the past week, 2.5% over the past month, 2.3% year to date and 12.8% over the last year, while the 3 year and 5 year returns sit at 57.9% and 119.3%. These moves sit against a backdrop of ongoing interest in the big Australian banks and regular updates on credit conditions,...
NYSE:SLB
NYSE:SLBEnergy Services

Assessing SLB (NYSE:SLB) Valuation After Recent Share Price Momentum And ChampionX Integration Story

Recent performance context for SLB (SLB) SLB (SLB) has drawn investor interest after a strong run over the past month and the past 3 months, with the stock up about 26% and 34% respectively, against a last close of $48.38. See our latest analysis for SLB. That recent surge sits on top of a year to date share price return of 20.35% and a 1 year total shareholder return of 23.91%. The 5 year total shareholder return of 115.35% shows the longer term picture has been strong, even though the 3...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

Could New PFOF Rules Quietly Reshape eToro Group’s (ETOR) Core Competitive Edge?

Recent industry attention on eToro Group has focused on how upcoming regulatory changes, including MiFID II amendments, DORA enforcement and a Payment-for-Order-Flow ban, are set to redefine operating standards for digital brokerage platforms. These shifts are expected to raise the bar on transparency, resilience and data connectivity, offering larger players such as eToro an opportunity to deepen user engagement and reinforce trust through stronger compliance and richer account aggregation...
NYSE:DAL
NYSE:DALAirlines

Should Delta’s Long‑Dated Widebody Bet Redefine the Premium Story for Delta Air Lines (DAL) Investors?

In late January 2026, Delta Air Lines announced a major order for 31 Airbus A330-900 and A350-900 widebody jets, with options for 20 more, to refresh and expand its long-haul international fleet from 2029 onward while keeping its existing financial guidance unchanged. This long-dated, largely pre-financed fleet modernization underscores Delta’s intent to deepen its premium long-haul offering and sharpen its competitive position in global markets. We’ll now examine how this widebody fleet...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

AGNC Balances Strong Returns With More Cautious 2026 Investment Approach

AGNC Investment (NasdaqGS:AGNC) reported robust full-year economic returns for 2025. The company continued its high-yield monthly dividend policy, keeping the payout in double-digit territory. Management outlined a more cautious capital deployment and selective investment approach for 2026. The shift is linked to changing mortgage market conditions, including tighter spreads and prepayment risks. AGNC Investment (NasdaqGS:AGNC) focuses on mortgage backed securities, so shifts in mortgage...
NasdaqGS:KHC
NasdaqGS:KHCFood

Is Kraft Heinz (KHC) Pricing Look Interesting After Recent Share Price Weakness

If you are trying to figure out whether Kraft Heinz is priced attractively right now, starting with how the current share price lines up against its fundamentals can be a useful first step. The stock recently closed at US$23.74, with returns of 2.3% over 7 days, a 2.1% decline over 30 days, a 2.7% decline year to date, and a 15.7% decline over 1 year, while the 3 year and 5 year returns stand at 30.0% and 11.4% declines respectively. Recent attention on Kraft Heinz has centered on how a well...
NYSE:GSL
NYSE:GSLShipping

Should GSL's Earnings Beat And Low Valuation Multiples Require Action From Global Ship Lease (GSL) Investors?

Global Ship Lease recently reported quarterly results that surpassed earnings expectations, reinforcing its reputation for consistent operational execution while the container shipping sector remains supportive. Despite this performance, the company continues to trade on relatively low valuation multiples against peers, drawing increased attention from value-focused investors who see its rising earnings estimates as a potential mismatch with its current market pricing. With these...
NYSE:MATX
NYSE:MATXShipping

A Look At Matson (MATX) Valuation After Strong Preliminary Q4 Results And Steady 2026 Outlook

Matson’s latest results and dividend decision Matson (MATX) shares are in focus after the company reported preliminary fourth quarter results that surpassed expectations, supported by stronger freight rates and volumes in its China service. See our latest analysis for Matson. Matson’s strong preliminary fourth quarter update and recent dividend declaration come after a sharp 58.79% 90 day share price return. The 5 year total shareholder return of 166.31% points to longer term compounding,...
TSXV:ASE
TSXV:ASEMetals and Mining

A Look At Asante Gold (TSXV:ASE) Valuation After Its CA$13.8m Private Placement Completion

Asante Gold (TSXV:ASE) has just closed a non brokered private placement, issuing 8,625,000 common shares at CA$1.60 each for gross proceeds of CA$13,800,000. The funds are intended to support its Bibiani and Chirano mines and general working capital. See our latest analysis for Asante Gold. The private placement comes after a mixed share price run, with a 13.9% 1 month share price return but a 9.6% 3 month share price decline. At the same time, the 1 year total shareholder return of 75.7% and...
WBAG:OMV
WBAG:OMVOil and Gas

RBC Downgrade and Green Hydrogen Pivot Could Be A Game Changer For OMV (WBAG:OMV)

In recent days, RBC Capital Markets downgraded Austrian energy group OMV, pointing to earnings pressure, structural challenges across key segments, and sizeable Q4 2025 non-cash impairments of €700,000,000.00. At the same time, OMV has secured up to €123,000,000.00 in funding for Austria’s largest green hydrogen project, highlighting a significant shift toward lower‑carbon energy within its long-term Strategy 2030 roadmap. We’ll now examine how RBC’s downgrade, alongside OMV’s major green...
NYSE:MCK
NYSE:MCKHealthcare

McKesson (MCK) Valuation Check After Completing Norway Exit And Refocusing On Core Growth Segments

McKesson (MCK) has completed the sale of its retail and distribution businesses in Norway, closing the chapter on its European exit and sharpening attention on Oncology, Multispecialty, and Biopharma Services platforms. See our latest analysis for McKesson. At a share price of $831.21, McKesson has seen modest recent share price gains, with a 90 day share price return of 2.45%, while the 1 year total shareholder return of 40.35% points to strong longer term momentum as the company refocuses...
TSX:WPM
TSX:WPMMetals and Mining

Assessing Wheaton Precious Metals (TSX:WPM) Valuation After All‑Time High And Hemlo Gold Stream Agreement

Wheaton Precious Metals (TSX:WPM) has drawn fresh attention after its shares touched an all time high, following a new gold stream agreement tied to the Hemlo Mine acquisition and supportive analyst commentary. See our latest analysis for Wheaton Precious Metals. The fresh all time high and Hemlo gold stream news come after a sharp 32.44% 90 day share price return and a 10.78% year to date share price gain, while the 1 year total shareholder return of 99.30% and 5 year total shareholder...
TSX:AGI
TSX:AGIMetals and Mining

A Look At Alamos Gold (TSX:AGI) Valuation After New Exploration Success Across Key Projects

Alamos Gold (TSX:AGI) has released fresh exploration results from several key assets, including Young-Davidson, Lynn Lake, and the Mulatos District, highlighting extended gold mineralization and new high-grade zones across multiple drilling campaigns. See our latest analysis for Alamos Gold. Despite the latest exploration updates, Alamos Gold's share price has pulled back recently, with a 7 day share price return of a 15.22% decline and a 30 day share price return of a 4.79% decline. At the...
TSX:FOM
TSX:FOMMetals and Mining

A Look At Foran Mining (TSX:FOM) Valuation After Hitting A New Yearly High On Project Progress And Sentiment

Why Foran Mining Is Back on Investors’ Radar Foran Mining (TSX:FOM) recently touched a new yearly high, drawing fresh attention to its copper and zinc projects along Saskatchewan’s Flin Flon Greenstone Belt, including the flagship McIlvenna Bay development. See our latest analysis for Foran Mining. The latest pullback, including a 7.18% 1 day share price decline to CA$6.59, follows a strong run, with a 30 day share price return of 30.75% and a 1 year total shareholder return of 73.42%. This...
LSE:RIO
LSE:RIOMetals and Mining

Rio Tinto AWS Copper Deal Highlights Opportunity In Low Carbon Growth

Rio Tinto Group and Amazon Web Services have agreed that AWS will be the first customer for Rio Tinto's low carbon copper produced using its Nuton bioleaching technology. The deal introduces Nuton copper into commercial use, with AWS planning to use the material in support of its sustainability goals in cloud and data center operations. Rio Tinto will also use AWS tools to help refine and scale the Nuton bioleaching process. For investors watching Rio Tinto Group (LSE:RIO), this news sits...
TSE:4523
TSE:4523Pharmaceuticals

Eisai (TSE:4523) Is Down 5.9% After Leqembi Subcutaneous Priority Review News - Has The Bull Case Changed?

In late January 2026, BioArctic’s partner Eisai reported regulatory progress for Leqembi (lecanemab), including an EMA filing for less frequent IV maintenance dosing and a US FDA Priority Review for a weekly subcutaneous autoinjector starting regimen in early Alzheimer’s disease. This shift toward at-home, less resource-intensive administration could materially influence how Leqembi is used across the treatment journey, potentially reshaping Eisai’s Alzheimer’s franchise profile. We will now...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi (ENXTPA:SAN) Valuation After Strong Results Buyback Expansion Dividend Hike And Positive Amlitelimab Data

Why Sanofi’s latest update matters for shareholders Sanofi (ENXTPA:SAN) has put several moving pieces on the table at once, with fresh 2025 results, higher shareholder payouts, a larger buyback, new 2026 guidance, and late stage amlitelimab data all landing together. See our latest analysis for Sanofi. Sanofi’s latest set of updates, including the amlitelimab phase 3 readouts, higher dividend, larger buyback and 2026 guidance, arrives after a period where momentum has cooled. The 90 day share...
NasdaqGM:LAND
NasdaqGM:LANDSpecialized REITs

A Look At Gladstone Land (LAND) Valuation After Preferred Redemption Plan And Earnings Update

Gladstone Land (LAND) is back in focus after confirming continued monthly cash distributions, setting a redemption date of January 30, 2026, for all Series D Preferred Stock, and scheduling its upcoming fourth quarter 2025 earnings release. See our latest analysis for Gladstone Land. The recent announcements on monthly distributions, preferred share redemption and the upcoming earnings release come after a strong run in the stock, with a 30 day share price return of 21.86% and a year to date...
NYSE:NEE
NYSE:NEEElectric Utilities

NextEra Energy (NEE) Valuation After Earnings Beat And Long Term Growth Targets In Power Demand And Data Centers

NextEra Energy (NEE) just delivered quarterly and full year 2025 earnings that topped profit expectations while slightly missing revenue estimates, and reaffirmed ambitious long term targets for both adjusted earnings and dividend growth. See our latest analysis for NextEra Energy. After the earnings release, the 1 month share price return of 9.49% and 1 year total shareholder return of 26.66% suggest momentum has been building as investors reassess both growth prospects and risk around its...
OM:SWED A
OM:SWED ABanks

Swedbank (OM:SWED A) Margin Holds Near 47.6% Challenging Cautious Profitability Narratives

Swedbank (OM:SWED A) has wrapped up FY 2025 with Q4 revenue of SEK16.98b and basic EPS of SEK7.26, alongside full year trailing revenue of SEK68.77b and EPS of SEK29.14 that give a clear view of the bank’s recent earnings power. Over the past few quarters the bank has seen revenue range between SEK16.81b and SEK17.50b per quarter, while quarterly EPS has moved between about SEK7.01 and SEK7.57. This sets the backdrop for how you might read today’s margin and profitability picture. With a...
TSE:285A
TSE:285ASemiconductor

Kioxia Holdings (TSE:285A) Valuation Check As CEO Transition To Hiroo Oota Draws Closer

Kioxia Holdings (TSE:285A) is in focus after announcing a CEO transition, with Nobuo Hayasaka set to step down and Hiroo Oota scheduled to assume the top role on April 1, 2026. See our latest analysis for Kioxia Holdings. That leadership news has landed alongside strong recent momentum, with a 1 month share price return of 104.7% and year to date share price return of 88.2% at a last close of ¥21,360. The 1 year total shareholder return is very large at around 11x, suggesting investors have...
BIT:TPRO
BIT:TPROSemiconductor

A Look At Technoprobe (BIT:TPRO) Valuation After Sector Jitters From Intel AI Chip Supply Warning

Weakness across semiconductor stocks after Intel flagged supply constraints for AI server chips has put Technoprobe (BIT:TPRO) back in focus, as investors weigh sector driven sentiment against the company’s recent share performance. See our latest analysis for Technoprobe. After a softer recent patch linked to sector wide worries, Technoprobe’s share price has a 30 day share price return of 28.11% and a 90 day share price return of 66.28%. The 1 year total shareholder return of 155.81% and 3...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Should FDA’s New Colorectal Cancer CDx Approval Reshape Guardant Health’s (GH) Liquid Biopsy Investment Case?

Guardant Health announced that the FDA has approved its Guardant360 CDx liquid biopsy as a companion diagnostic to identify patients with BRAF V600E‑mutant metastatic colorectal cancer eligible for encorafenib plus cetuximab and chemotherapy. This approval adds colorectal cancer to Guardant360 CDx’s growing list of companion diagnostic indications, reinforcing the role of non‑invasive genomic profiling in enabling targeted treatment decisions when tissue is limited or unavailable. We’ll now...